Patients in the UK will get early access to Dompé farmaceutici's neurotrophic keratitis drug Oxervate (cenegermin), the Medicines and Healthcare products Regulatory Agency (MHRA) announced Wednesday.
OxervateUSPackag_1534470705843-3-HR The safety and efficacy of Oxervate was evaluated in 2 independent, double-masked, randomized, multicenter, controlled clinical trials involving patients with ...
Please provide your email address to receive an email when new articles are posted on . There is more than one way to treat neurotrophic keratopathy. In a debate on the topic, Fasika Woreta, MD, MPH, ...
Please provide your email address to receive an email when new articles are posted on . Stonecipher, a cornea specialist at the University of North Carolina and Tulane, called Oxervate ...
Dompé, a biopharmaceutical company, announced that the Committee for Human Medicinal Products (CHMP) of European Medicines Agency (EMA) has released a positive opinion, recommending the marketing ...
MILAN and SAN BRUNO, Calif., March 12, 2019 /PRNewswire/ -- Dompé Farmaceutici S.p.A and Dompé U.S. Inc., (collectively Dompé), announced today that the National Organization for Rare Disorders (NORD) ...
The safety and efficacy of Oxervate, a topical eye drop containing cenegermin, was studied in a total of 151 patients with neurotrophic keratitis in two, eight-week, randomized controlled multi-center ...
MILAN, Nov. 26, 2020 /PRNewswire/ -- Dompé farmaceutici Spa and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive ...
Aug. 23 (UPI) --The U.S. Food and Drug Administration approved the first medication to treat a rare eye disease affecting the cornea. Dompe farmaceutici SpA, an Italian bio-pharmaceutical company, can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results